Explore
Validate
Learn13684
antibody from Cell Signaling Technology, Inc
Targeting: CD274
B7-H, B7-H1, B7H1, PD-L1, PDCD1LG1, PDL1
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [11]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 13684 - Provider product page
- Provider
- Cell Signaling Technology, Inc
- Proper citation
- Cell Signaling Technology Cat#13684, RRID:AB_2687655
- Product name
- PD-L1 (E1L3N®) XP® Rabbit mAb
- Antibody type
- Monoclonal
- Reactivity
- Human
- Host
- Rabbit
- Storage
- -20°C
Submitted references STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.
Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer.
PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status.
Nodal metastasis in cervical cancer occurs in clearly delineated fields of immune suppression in the pelvic lymph catchment area.
Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma.
The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs.
PD-L1 expression in small cell neuroendocrine carcinomas.
UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas.
EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy.
Koyama S, Akbay EA, Li YY, Aref AR, Skoulidis F, Herter-Sprie GS, Buczkowski KA, Liu Y, Awad MM, Denning WL, Diao L, Wang J, Parra-Cuentas ER, Wistuba II, Soucheray M, Thai T, Asahina H, Kitajima S, Altabef A, Cavanaugh JD, Rhee K, Gao P, Zhang H, Fecci PE, Shimamura T, Hellmann MD, Heymach JV, Hodi FS, Freeman GJ, Barbie DA, Dranoff G, Hammerman PS, Wong KK
Cancer research 2016 Mar 1;76(5):999-1008
Cancer research 2016 Mar 1;76(5):999-1008
Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer.
Lastwika KJ, Wilson W 3rd, Li QK, Norris J, Xu H, Ghazarian SR, Kitagawa H, Kawabata S, Taube JM, Yao S, Liu LN, Gills JJ, Dennis PA
Cancer research 2016 Jan 15;76(2):227-38
Cancer research 2016 Jan 15;76(2):227-38
PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
Schmidt LH, Kümmel A, Görlich D, Mohr M, Bröckling S, Mikesch JH, Grünewald I, Marra A, Schultheis AM, Wardelmann E, Müller-Tidow C, Spieker T, Schliemann C, Berdel WE, Wiewrodt R, Hartmann W
PloS one 2015;10(8):e0136023
PloS one 2015;10(8):e0136023
Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
Cedrés S, Ponce-Aix S, Zugazagoitia J, Sansano I, Enguita A, Navarro-Mendivil A, Martinez-Marti A, Martinez P, Felip E
PloS one 2015;10(3):e0121071
PloS one 2015;10(3):e0121071
Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status.
Koh J, Go H, Keam B, Kim MY, Nam SJ, Kim TM, Lee SH, Min HS, Kim YT, Kim DW, Jeon YK, Chung DH
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2015 Sep;28(9):1154-66
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2015 Sep;28(9):1154-66
Nodal metastasis in cervical cancer occurs in clearly delineated fields of immune suppression in the pelvic lymph catchment area.
Heeren AM, de Boer E, Bleeker MC, Musters RJ, Buist MR, Kenter GG, de Gruijl TD, Jordanova ES
Oncotarget 2015 Oct 20;6(32):32484-93
Oncotarget 2015 Oct 20;6(32):32484-93
Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma.
Katsuya Y, Fujita Y, Horinouchi H, Ohe Y, Watanabe S, Tsuta K
Lung cancer (Amsterdam, Netherlands) 2015 May;88(2):154-9
Lung cancer (Amsterdam, Netherlands) 2015 May;88(2):154-9
The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs.
Tang Y, Fang W, Zhang Y, Hong S, Kang S, Yan Y, Chen N, Zhan J, He X, Qin T, Li G, Tang W, Peng P, Zhang L
Oncotarget 2015 Jun 10;6(16):14209-19
Oncotarget 2015 Jun 10;6(16):14209-19
PD-L1 expression in small cell neuroendocrine carcinomas.
Schultheis AM, Scheel AH, Ozretić L, George J, Thomas RK, Hagemann T, Zander T, Wolf J, Buettner R
European journal of cancer (Oxford, England : 1990) 2015 Feb;51(3):421-6
European journal of cancer (Oxford, England : 1990) 2015 Feb;51(3):421-6
UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas.
Wong SQ, Waldeck K, Vergara IA, Schröder J, Madore J, Wilmott JS, Colebatch AJ, De Paoli-Iseppi R, Li J, Lupat R, Semple T, Arnau GM, Fellowes A, Leonard JH, Hruby G, Mann GJ, Thompson JF, Cullinane C, Johnston M, Shackleton M, Sandhu S, Bowtell DD, Johnstone RW, Fox SB, McArthur GA, Papenfuss AT, Scolyer RA, Gill AJ, Hicks RJ, Tothill RW
Cancer research 2015 Dec 15;75(24):5228-34
Cancer research 2015 Dec 15;75(24):5228-34
EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy.
Fang W, Zhang J, Hong S, Zhan J, Chen N, Qin T, Tang Y, Zhang Y, Kang S, Zhou T, Wu X, Liang W, Hu Z, Ma Y, Zhao Y, Tian Y, Yang Y, Xue C, Yan Y, Hou X, Huang P, Huang Y, Zhao H, Zhang L
Oncotarget 2014 Dec 15;5(23):12189-202
Oncotarget 2014 Dec 15;5(23):12189-202
No comments: Submit comment
No validations: Submit validation data